Luglio/Agosto - Sigot.Org

BIBLIOGRAFIA
1. ALEXANDERSEN P., CHRISTIANSEN C.: The
aging male: testosterone deficiency and testosterone
replacement. An up-date. Atherosclerosis. 2004;
173:157-169.
2. ALLAN C.A., MCLACHLAN R.I.: Age-related
changes in testosterone and the role of replacement
therapy in older men. Clin Endocrinol (Oxf). 2004;
60: 653-670.
3. COMHAIRE F.H.: Andropause: replacement therapy
in the ageing male. Eur Urol. 2000; 38: 655-662.
4. HIJAZI R.A., CUNNINGHAM G.R.: Andropause:
is androgen replacement therapy indicated for the
aging male? Annu Rev Med. 2005; 56: 117-137.
5. MORALES A., LUNENFELD B.: International
Society for the Study of the Aging Male.
Investigation, treatment and monitoring of late-onset
hypogonadism in males. Official recommendations
of ISSAM. International Society for the Study of the
Aging Male. Aging Male. 2002; 5: 74-86.
6. LUNENFELD B., SAAD F., HOESL C.E.: ISA,
ISSAM and EAU recommendations for the investigation,
treatment and monitoring of late-onset
hypogonadism in males: scientific background and
rationale. Aging Male. 2005; 8: 59-74.
7. NIESCHLAG E., SWERDLOFF R., BEHRE H.M.,
GOOREN L.J., KAUFMAN J.M., LEGROS J.J.,
LUNENFELD B., MORLEY J.E., SCHULMAN C.,
WANG C., WEIDNER W., WU F.C.: International
Society of Andrology (ISA); International Society
for the Study of the Aging Male (ISSAM);
European Association of Urology (EAU).
Investigation, treatment and monitoring of lateonset
hypogonadism in males. ISA, ISSAM, and
EAU recommendations. Eur Urol. 2005; 48: 1-4.
8. VALENTI G., BOSSONI S., GIUSTINA A., et al.:
Italian Study Group on Geriatric Endocrinology.
Consensus Document on substitution therapy with
testosterone in hypoandrogenic elderly men. Aging
Clin Exp Res. 2002; 14: 439-464.
9. BHASIN S., WOODHOUSE L., CASABURI R.,
SINGH A.B., MAC R.P., LEE M., YARASHESKI
K.E., SINHA-HIKIM I., DZEKOV C., DZEKOV J.,
MAGLIANO L., STORER T.W.: Older men are as
responsive as young men to the anabolic effects of
graded doses of testosterone on the skeletal muscle.
J Clin Endocrinol Metab. 2005; 90: 678-88.
10. MAKHSIDA N., SHAH J., YAN G., FISCH H.,
SHABSIGH R.: Hypogonadism and metabolic syndrome:
implications for testosterone therapy. J
Urol. 2005; 174: 827-834.
11. SHABSIGH R., KATZ M., YAN G., MAKHSIDA
N.: Cardiovascular issues in hypogonadism and
testosterone therapy. Am J Cardiol. 2005; 96(12B):
67M-72M.
12. SCHLEICH F., LEGROS J.J.: Effects of androgen
substitution on lipid profile in the adult and aging
hypogonadal male. Eur J Endocrinol. 2004; 151:
415-424.
13. ISIDORI A., FATTORINI G., LATINI M.,
ROMANELLI F.: Invecchiamento dell’uomo: esiste
l’andropausa? La Medicina Estetica. 2002; 26: 241-247.
14. BASARIA S.: Andropause: need for concrete
guidelines until more evidence becomes available. J
Endocrinol Invest. 2005; 28: 667-670.
15. HANDELSMAN D.J., LIU P.Y.: Andropause:
Geriatria
invention, prevention, rejuvenation. Trends
Endocrinol Metab. 2005; 16: 39-45.
16. DI GIORGIO M.R., SOFIA A., FATTORINI G.,
LATINI M., ROMANELLI F.: Deficienza androgena
parziale nell’invecchiamento degli uomini. La
Medicina Estetica 2005; 29: 509-513.
17. TARIQ S.H., HAREN M.T., KIM M.J., MORLEY
J.E.: Andropause: is the emperor wearing any
clothes? Rev Endocr Metab Disord. 2005; 6: 77-84.
18. LATINI M., CONTE D., ISIDORI A.,
ROMANELLI F.: Gonadal function changes in
healthy, aging men. J Endocrinol Invest 2002; 25:
89-90.
19. EBERT T., JOCKENHOVEL F., MORALES A.,
SHABSIGH R.: The current status of therapy for
symptomatic late-onset hypogonadism with transdermal
testosterone gel. Eur Urol. 2005; 47: 137-146.
20. BARQAWI A., CRAWFORD E.D.: Testosterone
replacement therapy and the risk of prostate cancer.
Is there a link? Int J Impot Res. 10 November
2005; doi: 10.1038/sj.ijir.3901418.
21. WALD M., MEACHAM R.B., ROSS L.S.,
NIEDERBERGER C.S.: Testosterone replacement
therapy for older men. J Androl. 2006; 27: 126-132.
22. JOCKENHOVEL F.: Testosterone therapy-what,
when and to whom? Aging Male. 2004; 7:
319-324.
23. SEFTEL A.: Testosterone replacement therapy
for male hypogonadism: Part III. Pharmacologic
and clinical profiles, monitoring, safety issues, and
potential future agents. Int J Impot Res. 29
September 2005; doi: 10.1038/sj.ijir.3901366.
24. VERMEULEN A.: Androgen replacement therapy
in the aging male-a critical evaluation. J Clin
Endocrinol Metab. 2001; 86: 2380-2390.
25. KAUFMAN J.: A rational approach to androgen
therapy for hypogonadal men with prostate cancer.
Int J Impot Res. 2006; 18: 26-31.
26. KIRBY R., GOULD D.: Testosterone replacement
therapy in hypogonadal men and prostate
cancer risk. BJU Int. 2005; 96: 471-472.
27. RHODEN E.L., MORGENTALER A.: Influence
of demographic factors and biochemical characteristics
on the prostate-specific antigen (PSA) response
to testosterone replacement therapy. Int J Impot
Res. 2006; 18: 201-205.
28. LIU P.Y., SWERDLOFF R.S., VELDHUIS J.D.:
Clinical review 171: The rationale, efficacy and
safety of androgen therapy in older men: future
research and current practice recommendations. J
Clin Endocrinol Metab. 2004; 89: 4789-4796.
29. MORALES A.: Monitoring androgen replacement
therapy: testosterone and prostate safety. J
Endocrinol Invest. 2005; 28:122-127.
30. AVERSA A., ISIDORI A.M., SPERA G., LENZI
A., FABBRI A.: Androgens improve cavernous
vasodilation and response to sildenafil in patients
with erectile dysfunction. Clin Endocrinol (Oxf).
2003; 58: 632-638.
31. GREENSTEIN A., MABJEESH N.J., SOFER M.,
KAVER I., MATZKIN H., CHEN J.: Does sildenafil
combined with testosterone gel improve erectile
dysfunction in hypogonadal men in whom testosterone
supplement therapy alone failed? J Urol.
2005; 173: 530-532.
Vol. XVIII n. 4 - Luglio/Agosto 2006 223